8-KRegulation FDExhibits & Filings

DEXCOM INC 8-K Report, Regulation FD Disclosure (Nov 16, 2007)

Filed November 16, 2007For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K report on November 16, 2007, announcing a significant regulatory milestone. The company received approval from the Food and Drug Administration (FDA) on November 15, 2007, to calibrate its SEVENTM seven-day continuous glucose monitoring (CGM) system using any FDA-cleared blood glucose meter. This approval represents a key enhancement to DexCom's product offering, providing greater flexibility and convenience for users. The ability to use any FDA-cleared meter for calibration removes a potential barrier to adoption and improves the user experience for individuals managing diabetes. This regulatory clearance is expected to enhance the marketability and accessibility of the SEVENTM system, potentially driving increased sales and market share for DexCom. Investors should view this development positively as it strengthens the product's competitive position and addresses user needs.

Key Highlights

  • 1DexCom received FDA approval on November 15, 2007, to calibrate its SEVENTM continuous glucose monitoring system.
  • 2The SEVENTM system can now be calibrated using any FDA-cleared blood glucose meter.
  • 3This approval enhances the flexibility and user-friendliness of DexCom's CGM technology.
  • 4The SEVENTM is a seven-day continuous glucose monitoring system.
  • 5The company issued a press release as Exhibit 99.01 detailing this FDA approval.
  • 6This regulatory update is considered a Regulation FD Disclosure.
  • 7The filing date of the 8-K report is November 16, 2007.

Frequently Asked Questions

The main significance is that DexCom's SEVENTM continuous glucose monitoring system can now be calibrated using any FDA-cleared blood glucose meter. This provides users with greater flexibility and convenience compared to potentially being restricted to specific meters.

This approval enhances the SEVENTM system's usability and market appeal by removing a potential limitation. It makes the system more accessible to a wider range of users who may already own an FDA-cleared blood glucose meter, potentially driving broader adoption.

Regulation FD (Fair Disclosure) ensures that material information is broadly disseminated to the public simultaneously, rather than selectively to certain individuals. In this case, DexCom is publicly announcing the FDA approval to all investors at the same time.

The SEVENTM is DexCom's seven-day continuous glucose monitoring system designed to help individuals manage diabetes by providing real-time glucose readings.